{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:19Z","timestamp":1791849499710,"version":"4.3.4"},"reference-count":28,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD) affecting mineral and bone metabolism and characterized by excessive parathyroid hormone (PTH) production and parathyroid hyperplasia.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The objective of this analysis was to compare the efficacy and adverse effects of extended-release calcifediol (ERC) and paricalcitol (PCT) by assessing their effect on the biomarkers PTH, calcium, and phosphate in patients with non-dialysis CKD (ND-CKD).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A systematic literature research was performed in PubMed to identify randomized control trials (RCTs). Quality assessment was done with the GRADE method. The effects of ERC vs PCT were compared using random effects in a frequentist setting.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Nine RCTs comprising 1426 patients were included in the analyses. The analyses were performed on 2 overlapping networks, due to nonreporting of outcomes in some of the included studies. No head-to-head trials were identified. No statistically significant differences in PTH reduction were found between PCT and ERC. Treatment with PCT showed statistically significant increases in calcium compared with ERC (0.2 mg\/dL increase; 95% CI, \u22120.37 to \u22120.05 mg\/dL). No differences in effects on phosphate were observed.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This network meta-analysis showed that ERC is comparable in lowering PTH levels vs PCT. ERC displayed avoidance of potentially clinically relevant increases in serum calcium, offering an effective and well-tolerated treatment option for the management of SHPT in patients with ND-CKD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgad289","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T19:15:03Z","timestamp":1685128503000},"page":"e1424-e1432","source":"Crossref","is-referenced-by-count":13,"title":["Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-8057","authenticated-orcid":false,"given":"Matteo","family":"Franchi","sequence":"first","affiliation":[{"name":"Department of Statistics and Quantitative Methods, Bicocca University Milan , 20126 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-1682","authenticated-orcid":false,"given":"Joel","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Quantify Research , 112 21 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Gonzales-Parra","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension Clinic, Fundaci\u00f3n Jim\u00e9nez D\u00edaz , 28040 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anibal","family":"Ferreira","sequence":"additional","affiliation":[{"name":"NOVA Medical School, Faculty of Medical Sciences, Nova University of Lisbon , 1169-056 Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Str\u00f6m","sequence":"additional","affiliation":[{"name":"Quantify Research , 112 21 Stockholm , Sweden"},{"name":"Department of Medicine, Huddinge, Karolinska Institutet , 141 57 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-8444","authenticated-orcid":false,"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[{"name":"Department of Statistics and Quantitative Methods, Bicocca University Milan , 20126 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"Suppl 1","key":"2023101816071321600_dgad289-B1","first-page":"i2","article-title":"The pathophysiology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS","volume":"1","author":"Cannata-Andia","year":"2008","journal-title":"NDT Plus"},{"issue":"2","key":"2023101816071321600_dgad289-B2","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13196","article-title":"FGF23 And the PTH response to paricalcitol in chronic kidney disease","volume":"50","author":"D'Arrigo","year":"2020","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"2023101816071321600_dgad289-B3","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","article-title":"Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol","volume":"27","author":"Hansen","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2023101816071321600_dgad289-B4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","article-title":"Paricalcitol and endothelial function in chronic kidney disease trial","volume":"64","author":"Zoccali","year":"2014","journal-title":"Hypertension"},{"issue":"7","key":"2023101816071321600_dgad289-B5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"2023101816071321600_dgad289-B6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2013the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2023101816071321600_dgad289-B7","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/ckj\/sfab091","article-title":"Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis","volume":"14","author":"Cozzolino","year":"2021","journal-title":"Clin Kidney J"},{"issue":"1","key":"2023101816071321600_dgad289-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2023101816071321600_dgad289-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2023101816071321600_dgad289-B10","volume-title":"Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach (Updated October 2013)","author":"Sch\u00fcnemann","year":"2013"},{"key":"2023101816071321600_dgad289-B11","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"3","key":"2023101816071321600_dgad289-B12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"2023101816071321600_dgad289-B13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"issue":"4","key":"2023101816071321600_dgad289-B14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"issue":"2","key":"2023101816071321600_dgad289-B15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2023101816071321600_dgad289-B16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","article-title":"Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial","volume":"52","author":"Alborzi","year":"2008","journal-title":"Hypertension"},{"issue":"6","key":"2023101816071321600_dgad289-B17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1159\/000369939","article-title":"Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"40","author":"Sprague","year":"2014","journal-title":"Am J Nephrol"},{"issue":"9","key":"2023101816071321600_dgad289-B18","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/ndt\/gft227","article-title":"Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study","volume":"28","author":"Coyne","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2023101816071321600_dgad289-B19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000441364","article-title":"Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial","volume":"42","author":"Lundwall","year":"2015","journal-title":"Am J Nephrol"},{"issue":"4","key":"2023101816071321600_dgad289-B20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"2023101816071321600_dgad289-B21","author":"Franchi","year":"2023"},{"issue":"9","key":"2023101816071321600_dgad289-B22","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2023101816071321600_dgad289-B23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118174","article-title":"Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial","volume":"10","author":"Riccio","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"2023101816071321600_dgad289-B24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11255-015-1195-6","article-title":"Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Cai","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"2023101816071321600_dgad289-B25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000529523","article-title":"Evaluation of therapies for secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"9","author":"Strugnell","year":"2023","journal-title":"Kidney Dis (Basel)"},{"key":"2023101816071321600_dgad289-B26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","article-title":"Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation","volume":"148","author":"Petkovich","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2023101816071321600_dgad289-B27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am J Nephrol"},{"key":"2023101816071321600_dgad289-B28","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/320560","article-title":"Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease","volume":"2013","author":"Han","year":"2013","journal-title":"Biomed Res Int"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad289\/50516019\/dgad289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/e1424\/52218130\/dgad289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/e1424\/52218130\/dgad289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T16:15:59Z","timestamp":1697645759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/11\/e1424\/7180818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,26]]},"published-print":{"date-parts":[[2023,10,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad289","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,26]]}}}